Piracetam for Treatment of Cocaine Addiction, Phase II - 4

This study has been withdrawn prior to enrollment.
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
First received: September 20, 1999
Last updated: July 25, 2013
Last verified: July 2013

The purpose of this study is to follow patients in Phase I of an inpatient study in an eight week open label assessment of piracetam in an outpatient treatment program.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Piracetam
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Piracetam for Treatment of Cocaine Addiction, Phase II

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Drug use
  • Adverse effects
  • Clinical status

Enrollment: 0

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000199

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000199     History of Changes
Other Study ID Numbers: NIDA-00238-4, K20DA000238, K02-00238-4
Study First Received: September 20, 1999
Last Updated: July 25, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Nootropic Agents

ClinicalTrials.gov processed this record on April 15, 2014